These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273 [TBL] [Abstract][Full Text] [Related]
5. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for recurrent malignant glioma: an interim report on survival. Ingram M; Buckwalter JG; Jacques DB; Freshwater DB; Abts RM; Techy GB; Miyagi K; Shelden CH; Rand RW; English LW Neurol Res; 1990 Dec; 12(4):265-73. PubMed ID: 1982172 [TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors. Grimm EA Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948 [No Abstract] [Full Text] [Related]
9. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. Jeffes EW; Beamer YB; Jacques S; Silberman RS; Vayuvegula B; Gupta S; Coss JS; Yamamoto RS; Granger GA J Neurooncol; 1993 Feb; 15(2):141-55. PubMed ID: 8509819 [TBL] [Abstract][Full Text] [Related]
11. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Yoshida S; Tanaka R; Takai N; Ono K Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma. Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079 [TBL] [Abstract][Full Text] [Related]
13. Therapy of recurrent high-grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro. Jeffes EW; Beamer YB; Jacques S; Coss JS; Nep RL; Beckman M; Yamamoto RS; Granger G Lymphokine Cytokine Res; 1991 Apr; 10(1-2):89-94. PubMed ID: 1873360 [TBL] [Abstract][Full Text] [Related]
14. Autologous natural killer cell therapy for human recurrent malignant glioma. Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367 [TBL] [Abstract][Full Text] [Related]
15. Treatment of glioma with intratumoral instillation of autologous lymphocytes. Bhagwati SN Childs Nerv Syst; 1989 Feb; 5(1):38-40. PubMed ID: 2702675 [TBL] [Abstract][Full Text] [Related]
16. Systemic T cell adoptive immunotherapy of malignant gliomas. Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171 [TBL] [Abstract][Full Text] [Related]
17. Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports. Atkinson LL; Merchant RE; Ghatak NR; Young HF Neurosurgery; 1989 Nov; 25(5):805-10. PubMed ID: 2586734 [TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Merchant RE; Baldwin NG; Rice CD; Bear HD Neurol Res; 1997 Apr; 19(2):145-52. PubMed ID: 9175143 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465 [TBL] [Abstract][Full Text] [Related]